LWLG 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• During the six months ended June 30, 2026, we recognized $61,918 of licensing and royalty revenue. During the six months ended June 30, 2025, we recognized $48,522 of licensing and royalty revenue.

• During the six months ended June 30, 2026, we recognized $1,336 in cost of sales. During the six months ended June 30, 2025, we recognized $5,491 in cost of sales.

• Research and development expenses increased for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, primarily due to increases in salary and employee benefits expenses, non-cash stock compensation expenses, laboratory materials and supplies expenses, and prototype …

• We expect to continue to incur substantial research and development expenses developing and commercializing our electro-optic materials platform. These expenses will increase because of accelerated development efforts to support commercialization of our non-linear optical polymer materials technolog…

• General and administrative expenses increased for the six months ended June 30, 2026, as compared to the six months ended June 30, 2025, primarily due to increases in non-cash stock-based compensation expenses, salary and employee benefits expenses and payroll taxes, recruiting fees, professional se…

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• Our primary source of operating cash inflows was (i) proceeds from sale of common stock by Roth Capital Partners, LLC (investment banking company) (“Roth Capital”) pursuant to the at-the-market sales agreement with Roth Capital as described in Note 10 to the Financial Statements, (ii) proceeds from …

• On December 15, 2025, we entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as the underwriter (the “Underwriter”), relating to an underwritten public offering of 11,666,667 shares of the Company’s common…

• On March 17, 2025, we entered into a purchase agreement with Lincoln Park (the “2025 Purchase Agreement”) to sell up to $30,000,000 of registered common stock over a 36-month period. On December 12, 2025, the 2025 Purchase Agreement was terminated in conjunction with the Titan Offering.

• On December 9, 2022, we entered into the at-the-market sales agreement with Roth Capital, as sales agent, (the “Roth Sales Agreement”) pursuant to which we could offer and sell up to $35,000,000 in shares of our registered common stock, from time to time through Roth Capital. On April 20, 2026, the …

• During the three months ended March 31, 2026, the Company received $6,544,407 in proceeds pursuant to the Roth Sales Agreement, $4,930,928 in proceeds from the exercise of over-allotment option from the Titan Offering, and $1,862,119 in proceeds from the exercise of options.